Business Wire

C3.ai Digital Transformation Institute Announces Call for Papers to Advance AI for Energy and Climate Security

2.2.2021 14:00:00 EET | Business Wire | Press release

Share

The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to address the challenge of re-envisioning energy systems with artificial intelligence (AI) and digital transformation to lead the way to a lower-carbon, higher-efficiency economy that will enhance both energy and climate security.

“Mitigating the impact of global energy generation will require a massive transformation of the world’s energy infrastructure,” said Thomas M. Siebel, chairman and CEO of C3 AI, a leading enterprise AI software provider for accelerating digital transformation. “This call for proposals covers topics that aim to provide safer, cleaner, lower cost, and more reliable energy through the application of AI.”

Immediate Call for Proposals : AI and Digital Transformation for Energy and Climate Security.

Topics for research awards may include, but are not limited to, the following:

  1. Sustainability: Applying AI, machine learning, and advanced analytic techniques to support sustainability initiatives for energy consumption and greenhouse gas emissions

  2. AI for Carbon Sequestration: Applying AI/ML techniques to increase the scale and reduce the cost of carbon sequestration

  3. AI for Leaks and Emissions Detection: Applying advanced AI/ML techniques for large-scale emissions detection, facility-level data reconciliation and gap analysis for emissions sensors, prediction of emissions risk, and analysis and optimization of flaring intensity across upstream and downstream operations

  4. Safe Hydrocarbon Production and Transportation Infrastructure: Applying analytic and AI/ML modeling techniques to increase the safety and reduce emissions from oil and gas extraction, petrochemical production, and hydrocarbon transportation

  5. AI for Advanced Energy and Carbon Markets: Enabling dynamic, automated, and real-time pricing of energy generation sources

  6. Cybersecurity of Power and Energy Infrastructure: Leveraging AI/ML techniques to improve the cybersecurity of our critical power and energy assets, as well as smart connected factories and homes

  7. Smart Grid Analytics: Applying AI and other analytic approaches to improve the efficiency and effectiveness of grid transmission and distribution operations

  8. Distributed Energy Resource Management: Applying AI to increase the penetration and use of distributed renewables

  9. AI for Energy-Efficient Buildings and Factories: Leveraging AI techniques for advanced building and factory control to improve energy efficiency

  10. AI for Improved Natural Catastrophe Risk Assessment: Applying AI to improve modeling of natural catastrophe risks from future weather-related events (e.g., tropical storms, wildfires, and floods)

  11. Resilient Energy Systems: Addressing how the use of AI/ML techniques and markets for energy and carbon introduce new vulnerabilities

  12. AI for Improved Climate Change Modeling: Use of AI/ML to address climate change modeling and adaptation

“The energy industry is at a critical inflection point to accelerate delivery of cleaner, safer energy while meeting growing demand,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes, an energy technology company serving energy and industrial customers worldwide. “We are excited about our partnership with the C3.ai Digital Transformation Institute and the impact these funded research projects will have in advancing AI at scale for the energy transition.”

This second call for proposals is open now, with a submission deadline of March 29, 2021. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Selected proposals will be announced in mid-May, with start dates of June 1, 2021.

Up to $5 million in cash awards will be funded from this second call, ranging from $100,000 to $250,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite, access to the Microsoft Azure cloud platform, and access to the Blue Waters supercomputer at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign.

Establishing the New Science of Digital Transformation

C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.

About C3.ai Digital Transformation Institute

C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, IoT, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed and hosted by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
Tel. +1 510-295-9685
Kstann@berkeley.edu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye